Dr. Kris on the EML4-ALK Translocation in Lung Cancer

Video

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York on the EML4-ALK Translocation

Mark G. Kris, MD, Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses how the crizotinib clinical trial changed the paradigm for treating patients with lung cancer who harbor an EML4-ALK translocation, at the 2010 ASCO Annual Meeting.

On August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non—small cell lung cancer (NSCLC).

Related Videos
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD
Emil Lou, MD, PhD, FACP
Jean L. Koff, MD, MS
Rohan Garje, MD
Debu Tripathy, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Benjamin Garmezy, MD